Hsbc Holdings PLC Reduces Stake in Silence Therapeutics plc (NASDAQ:SLN)

Hsbc Holdings PLC lessened its stake in shares of Silence Therapeutics plc (NASDAQ:SLN) by 2.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 172,834 shares of the company’s stock after selling 5,000 shares during the period. Hsbc Holdings PLC owned 0.58% of Silence Therapeutics worth $1,193,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Marshall Wace LLP increased its position in shares of Silence Therapeutics by 190.3% during the 4th quarter. Marshall Wace LLP now owns 488,889 shares of the company’s stock worth $3,364,000 after purchasing an additional 320,472 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Silence Therapeutics during the fourth quarter valued at about $438,000. Walleye Capital LLC purchased a new stake in shares of Silence Therapeutics in the 4th quarter valued at approximately $250,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Silence Therapeutics in the 4th quarter worth approximately $134,000. Finally, FNY Investment Advisers LLC acquired a new stake in Silence Therapeutics in the 4th quarter valued at approximately $120,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on SLN. Morgan Stanley lowered their price target on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. BMO Capital Markets dropped their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, March 4th. The Goldman Sachs Group reduced their price target on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a research report on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 7th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

Silence Therapeutics Trading Down 2.0 %

Shares of NASDAQ:SLN opened at $3.93 on Friday. The company has a market cap of $117.62 million, a PE ratio of -2.50 and a beta of 1.25. The company’s 50 day moving average is $3.47 and its two-hundred day moving average is $7.07. Silence Therapeutics plc has a 52 week low of $1.97 and a 52 week high of $24.38.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.